This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Antman EM et al. (2004) ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol 44: E1–E211
Yusuf S et al.; CREATE Trial Group Investigators (2005) Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. JAMA 293: 427–436
Yusuf S et al. (2006) Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354: 1464–1476
Buller HR et al. (2003) Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 349: 1695–1702
Buller HR et al. (2004) Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 140: 867–873
Acknowledgements
The synopsis was written by Hannah Camm, Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Linkins, LA., Weitz, J. OASIS-6: should patients with acute ST-segment elevation myocardial infarction be treated with fondaparinux?. Nat Rev Cardiol 3, 478–479 (2006). https://doi.org/10.1038/ncpcardio0635
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpcardio0635